NATICK, Mass., June 22 /PRNewswire/ -- Intact Medical Corporation, a leader in the development and marketing of minimally invasive systems for the diagnosis of breast cancer, today announced that the U.S. Patent and Trademark Office has awarded a new U.S. Patent, No. 7,041,101, entitled “Electrosurgical Accessing of Tissue with Controlled Collateral Thermal Phenomena” which relates to the Company’s Intact (TM) Breast Lesion Excision System (BLES). The patent involves the Company’s proprietary technology for interstitially located electrosurgical cutting, while protecting healthy tissue from collateral thermal trauma, as well as preventing thermal damage to any target tissue specimen to be retrieved for biopsy.
Commenting on today’s announcement, Christopher Bleck, President and Chief Executive Officer of Intact Medical Corporation said, “The issuance of this new patent further strengthens our position in the marketplace and increases the value of our intellectual property portfolio. The Company’s novel technology for the complete excision of breast lesions has had a major impact on the ability of the Intact BLES to deliver intact breast tissue samples in a minimally invasive procedure. By minimizing the amount of trauma during the procedure, we can prevent excess thermal damage to the target tissue in the intact sample. This is a major competitive advantage of the Intact BLES compared to conventional vacuum-assisted core needle biopsy procedures. By extracting a fully intact specimen, pathologists gain a more complete understanding of the suspect breast lesion, and in many cases, enable the avoidance of additional surgical procedures.”
The Intact Breast Lesion Excision System is a vacuum-assisted, image- guided biopsy device. The Intact procedure involves the insertion of a slender wand through a small incision in the breast to remove an intact sample of suspicious tissue for histopathological analysis. The procedure is performed under local anesthesia in an outpatient setting, with the actual capture of the breast lesion completed in less than 10 seconds. After the lesion is withdrawn, the incision is effectively closed with a bandage, requiring no stitches.
About Intact Medical Corporation
Founded in 1998, and based in Natick, Massachusetts, Intact Medical Corporation is a privately held company focused on the design, development and marketing of innovative, minimally invasive systems for the volumetric excision of tissue for diagnostic and therapeutic applications in select cancer markets. The Company’s lead product, the Intact Breast Lesion Excision System, received market clearance from the Food and Drug Administration in June 2001. Initial products are targeted at breast biopsy and the excision of benign lesions, potentially obviating the need for open surgical excisions. In August 2005, the company received expanded approval for the System, allowing its use to obtain tissue samples for histologic examination with partial or complete removal of an imaged abnormality, or partial removal of a palpable abnormality that has been classified as benign.
For more details on the Company, visit www.intactmedical.com Contact: Intact Medical Corporation Rx Communications Group Christopher Bleck, President and CEO Judith Sylk-Siegel (media) 508-655-7820 917-322-2164
Intact Medical Corporation
CONTACT: Christopher Bleck, President and CEO of Intact MedicalCorporation, +1-508-655-7820; or Judith Sylk-Siegel, media, of RxCommunications Group, +1-917-322-2164
Web site: http://www.intactmedical.com/
